Figure 3.

Proportional first incident use of glucagon-like peptide-1 receptor agonists as second line therapy after metformin in patients with established cardiovascular disease, and patients without established cardiovascular disease. ALPD=Australia Longitudinal Patient Database Practice Profile; CCAE=IBM MarketScan Commercial Claims and Encounters Data; CUIMC=Columbia University Irving Medical Center; FLPD=France Longitudinal Patient Database; GDA=Germany Disease Analyser; GLP-1 RA=glucagon-like peptide-1 receptor agonist; HIC=Health Informatics Centre at the University of Dundee; HKHA=Hong Kong Hospital Authority; IMRD=UK-IQVIA Medical Research Data; JHM=Johns Hopkins Medicine; MDCD=IBM Health MarketScan Multi-State Medicaid Database; MDCR=IBM Health MarketScan Medicare Supplemental and Coordination of Benefits Database; OCEDM=Optum Clinformatics Extended Data Mart - Date of Death; OEHR=Optum de-identified Electronic Health Record Dataset; SIDIAP=Information System for Research in Primary Care; STARR=Stanford Medicine; USOC=United States Open Claims; VA=Department of Veterans Affairs Healthcare System